BPC-157 vs. TB-500: Research Peptide Comparison

BPC-157 and TB-500 are two of the most frequently co-studied peptides in tissue-repair research, and Frontier Peptide Labs sells both individually and as a combined blend. They are structurally unrelated and act through different mechanisms, but their overlapping research applications make a side-by-side comparison useful for choosing — or combining — the right research tool.

What Is BPC-157?

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide (15 amino acids) derived from a partial sequence of a gastric protective protein originally isolated from rodent gastric juice. Across two decades of preclinical investigation, it has become a workhorse research tool for studying cytoprotection, angiogenesis, and connective-tissue repair. The most consistent mechanistic findings concern modulation of the nitric-oxide system and upregulation of growth-factor receptors: in rodent tendon and ligament injury models, treated animals showed accelerated tenocyte proliferation and faster collagen-fiber organization versus controls. BPC-157 has also been characterized for pro-angiogenic effects, promoting recruitment of collateral vessels in vascular-occlusion models and VEGFR2-dependent tube formation in cultured endothelial cells.

Read the full BPC-157 research summary →

What Is TB-500?

TB-500 is the synthetic research analog of Thymosin Beta-4 (TB-4), a 43-amino-acid G-actin-sequestering peptide first isolated from calf thymus. Its defining biochemical property is high-affinity binding to monomeric G-actin, which buffers the intracellular G-actin pool and modulates actin polymerization — a mechanism repeatedly linked to cell migration in scratch-wound assays using cultured keratinocytes and endothelial cells. Preclinical studies also characterize TB-4 as a potent angiogenic factor: in a murine hindlimb-ischemia model, it increased capillary density and improved perfusion, and in a mouse coronary-ligation model it increased neovascularization in the infarct border zone and reduced scar volume on histology.

Read the full TB-500 research summary →

Side-by-Side Comparison

	BPC-157	TB-500
Origin	Partial sequence of a gastric protective protein	Synthetic analog of Thymosin Beta-4 (calf thymus)
Structure	15-amino-acid pentadecapeptide	43-amino-acid peptide
Primary studied mechanism	Nitric-oxide modulation, growth-factor receptor upregulation	G-actin sequestration, actin polymerization dynamics
Studied applications	Tendon/ligament repair, GI cytoprotection, angiogenesis	Cell migration, angiogenesis, cardiac tissue models
Available on-site	BPC-157 Vial, BPC-157 Capsules	TB-500 Capsules

Why Some Research Protocols Use Them Together

Because BPC-157 and TB-500 act through distinct, non-overlapping mechanisms — nitric-oxide/growth-factor signaling versus actin-cytoskeleton dynamics — some laboratory protocols study them in combination to examine whether the two pathways produce additive or synergistic effects on tissue-repair endpoints. Frontier Peptide Labs supplies a co-lyophilized BPC-157 + TB-500 Blend Vial for laboratories running combined-protocol research, in addition to each compound individually. For guidance on reconstituting a blended vial correctly, see Working With Peptide Blends: Reconstitution Math for BPC-157 + TB-500.

Frequently Asked Questions

Are BPC-157 and TB-500 the same thing?
No. They are structurally unrelated peptides — a 15-amino-acid pentadecapeptide versus a 43-amino-acid actin-binding peptide — studied for different, non-overlapping mechanisms.

Can they be reconstituted together?
Yes, when supplied as a co-lyophilized blend vial. See Working With Peptide Blends: Reconstitution Math for BPC-157 + TB-500 for the math, and the Peptide Reconstitution Calculator to work out draw volumes.

Which formats are available?
BPC-157 is available as a Vial or Capsules; TB-500 is available as Capsules; both are also available in the co-lyophilized Blend Vial.

References

1. Sikiric P, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-32.
2. Cerovecki T, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res. 2010;28(9):1155-61.
3. Low TL, Hu SK, Goldstein AL. Complete amino acid sequence of bovine thymosin beta 4. Proc Natl Acad Sci U S A. 1981;78(2):1162-6.
4. Malinda KM, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-8.
5. Smart N, et al. Thymosin beta-4 induces adult epicardial progenitor mobilization. Nature. 2007;445(7124):177-82.

Research Use Only: This article and the products referenced are intended exclusively for laboratory research and development. They are not for human consumption, veterinary use, diagnostic use, cosmetic use, therapeutic application, or medical treatment. Purchasers are responsible for compliance with all applicable federal, state, and local regulations.